knowledge -WSS

knowledge

author：leisure time 2025-09-27 11:39:39 - browse：8349

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Wildfire pollution widens asthma inequities on Long Island

WSS

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

What to expect as Trump is arraigned on his Jan 6. indictment

Psychedelics group wrestles with new pharma identity

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medicare details structure of new drug price negotiation program

At least 13 dead in Texas as scorching temps continue

entertainment

knowledge

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

‘Oppenheimer’ and the risks of AI in health care

Tori Bowie and the unacceptable rates of Black maternal death

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

How to save PrEP access — and even expand it

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Duchenne breakthrough therapy leaves behind pioneering families

Moonlake's readout produced a cash windfall. Risks remain

DIEP, the 'gold standard' of breast reconstruction, is under threat

Walensky prepares to leave CDC — and Congress — behind

focus

Amazon expands telehealth clinic nationwide

ChatGPT in medicine: STAT answers readers' burning questions

Wildfire smoke exposes gaps in outdoor worker protections

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

United colonoscopy coverage change 'may cost lives,' doctors say

The high cost of giving birth even with insurance

focus

hotspot

focus

focus